WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

A new study has found that taking longer to reach the rapid eye movement (REM) stage of sleep is linked to a greater risk of ...

Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...

Parkinson’s dementia, vascular dementia and frontotemporal dementia—the condition affecting both Bruce Willis and Wendy ...

Taking longer to reach the rapid eye movement (REM) stage of sleep could mean you are more likely to develop dementia.

Annovis Bio (NYSE: ANVS) , a late-stage clinical drug company focused on neurodegenerative diseases, announced the closing of its underwritten public ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies fo ...

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will participate in a fireside chat at the Oppenheimer 25 th Annual ...

By Hunter Sowards Click here for updates on this story STOCKTON, California (KOVR) — Music is often considered the universal language, and at the University of the Pacific in Stockton, it’s also a ...

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that ...